Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PVT401 SAD and MAD in Healthy Subjects
NCT07423000Phase 1Recruiting
- Sponsor
- Parvus Therapeutics
- Start
- Apr 2026
- Primary completion
- Nov 2027
- Modality
- Peptides, Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PVT401 in inflammatory bowel disease (IBD) (4 arms), sponsored by Parvus Therapeutics. Primary endpoints: Adverse Events and Serious Adverse Events, Vital Signs (Temperature, Heart Rate, Blood Pressure) at 6 months and 2 more. Started Apr 2026; status: recruiting.
02
Drugs
PVT401
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT07423000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07423000.